Renovite
-
Biologics
Biocomposites’ investee Renovos Biologics receives FDA Breakthrough Device Designation for its synthetic nanoclay bone fusion gel, RENOVITE® BMP-2
RENOVITE® BMP-2 is being developed as an alternative to bone graft materials for interbody spinal fusion It is the first product…
Read More » -
Biologics
Biocomposites invests in Renovos Biologics – developers of the RENOVITE® nanoclay therapeutic delivery platform
RENOVITE ® nanoclay is a novel therapeutic delivery platform for precision regenerative medicine Investment will help fund pre-market approval for use in…
Read More »